ABBVIE
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 2013-01-01
- Employees
- -
- Market Cap
- $346B
- Website
- http://www.abbvie.com
A Study to Assess the Adverse Events and How Subcutaneous (SC) Injections and Intravenous (IV) Infusions of ABBV-142 Move Through the Body of Healthy Adult Participants
- First Posted Date
- 2025-01-14
- Last Posted Date
- 2025-01-24
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 74
- Registration Number
- NCT06774313
- Locations
- 🇺🇸
Acpru /Id# 271899, Grayslake, Illinois, United States
A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Budigalimab in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations
- Conditions
- Non Small Cell Lung Carcinoma
- Interventions
- First Posted Date
- 2025-01-13
- Last Posted Date
- 2025-05-16
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 172
- Registration Number
- NCT06772623
- Locations
- 🇺🇸
Providence - St. Jude Medical Center /ID# 271414, Fullerton, California, United States
🇺🇸FOMAT Medical Research - Clinica mi Salud by Focil Med /ID# 274450, Oxnard, California, United States
🇺🇸Mid Florida Hematology And Oncology Center /ID# 273777, Orange City, Florida, United States
Study to Assess Change in Disease Activity of Risankizumab Treatment in Adult Participants With Moderate to Severe Ulcerative Colitis
- Conditions
- Ulcerative Colitis
- First Posted Date
- 2025-01-08
- Last Posted Date
- 2025-04-18
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 200
- Registration Number
- NCT06764706
- Locations
- 🇩🇪
Gastroenterologie Rahlstedt /ID# 276408, Hamburg, Germany
🇩🇪Evangelisches Krankenhaus Kalk /ID# 276414, Cologne, Nordrhein-Westfalen, Germany
🇩🇪Dres. Kamp & Partner /ID# 275904, Minden, Nordrhein-Westfalen, Germany
An Ex-US Study to Assess Treatment Persistence With Risankizumab in Adult Participants With Psoriatic Arthritis
- Conditions
- Psoriatic Arthritis
- First Posted Date
- 2025-01-08
- Last Posted Date
- 2025-04-17
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 1200
- Registration Number
- NCT06764693
- Locations
- 🇩🇪
Klinische Forschung Im Medizinischen Versorgungalltag Gbr /ID# 276208, Planegg, Bayern, Germany
🇩🇪Rheumatologisch Immunologisch /ID# 275832, Templin, Brandenburg, Germany
🇩🇪Rheumatologische Facharztpraxis /ID# 276359, Magdeburg, Sachsen-Anhalt, Germany
A Study to Evaluate the Bioavailability and Food Effects of Oral Venetoclax New Tablet Formulation 2.0 in Healthy Adult Female Participants
- First Posted Date
- 2024-12-19
- Last Posted Date
- 2025-05-11
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 72
- Registration Number
- NCT06742086
- Locations
- 🇺🇸
Acpru /Id# 272979, Grayslake, Illinois, United States
A Study to Assess Change in How Oral Icalcaprant With Itraconazole Moves Through the Body in Healthy Adult Participants
- First Posted Date
- 2024-12-09
- Last Posted Date
- 2025-01-28
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 12
- Registration Number
- NCT06722430
- Locations
- 🇺🇸
Acpru /Id# 271617, Grayslake, Illinois, United States
A Single Dose Study to Assess Adverse Events and How Oral Icalcaprant Moves Through the Body in Healthy Adult Japanese and Han Chinese Participants
- First Posted Date
- 2024-12-09
- Last Posted Date
- 2025-01-28
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 16
- Registration Number
- NCT06722417
- Locations
- 🇺🇸
Anaheim Clinical Trials, LLC /ID# 271323, Anaheim, California, United States
A Study to Evaluate the Effectiveness and Safety of Treatments, Either Alone or in Combination, for the Treatment of Moderate to Severe Atopic Dermatitis
- First Posted Date
- 2024-12-05
- Last Posted Date
- 2025-05-20
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 80
- Registration Number
- NCT06718101
- Locations
- 🇺🇸
Integrative Skin Science and Research /ID# 274243, Sacramento, California, United States
🇺🇸Peak Dermatology Aesthetics and Wellness Fountain Hills /ID# 272550, Fountain Hills, Arizona, United States
🇺🇸Clinical Trials Research Institute /ID# 274234, Thousand Oaks, California, United States
A Comparison Study of Persistence of UPadacitinib vs. TNF-inhibitoRs In a German Real-world SettING
- Conditions
- Moderate to Severe Rheumatoid Arthritis
- First Posted Date
- 2024-12-02
- Last Posted Date
- 2025-04-22
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 678
- Registration Number
- NCT06712628
- Locations
- 🇩🇪
Rheumapraxis Heidelberg /ID# 276475, Heidelberg, Baden-Wuerttemberg, Germany
🇩🇪Rheumapraxis Haas Tübingen /ID# 275536, Tuebingen, Baden-Wuerttemberg, Germany
🇩🇪Rheumapraxis Ulm Dr. med. Nadia Rinaldi /ID# 276293, Ulm, Baden-Wuerttemberg, Germany
Safety and Efficacy of Upadacitinib in Combination With Topical Corticosteroids in Children From 2 to Less Than 12 Years of Age in Japan With Moderate to Severe Atopic Dermatitis
- First Posted Date
- 2024-11-22
- Last Posted Date
- 2025-03-27
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 98
- Registration Number
- NCT06701331
- Locations
- 🇯🇵
Miyata Dermatology Clinic /ID# 269200, Matsudo-Shi, Chiba, Japan
🇯🇵Tokunaga Skin Clinic /ID# 270189, Kasuga-shi, Fukuoka, Japan
🇯🇵Gunma University Hospital /ID# 272319, Maebashi, Gunma, Japan